Dyadic International Reports First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dyadic International Reports First Quarter 2015 Financial Results
  • Total Revenue up 35% Year-over-Year
  • Gross Profit up 70% Year-over-Year
  • Achieved Additional  C1 Research & Development Milestones from BASF
  • Four EU Funded Research Programs Approved for Start in 2015
  • Added New Board Member and Appointed New Chairman of Board
  • Raised $2 million in Private Placement

JUPITER, Fla., May 14, 2015 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today financial results for the quarter ended March 31, 2015. 

At March 31, 2015, cash and cash equivalents were approximately $3.7 million compared to $2.5 million at December 31, 2014.

Subsequent to the end of the quarter, the Company received $800,000 for achieving two additional research and development milestones in its funded research program from BASF, a Dyadic C1 Technology licensee.  The Company recognized $200,000 of the revenue for achievement of milestone 2 in March 2015 and will recognize $600,000 in April 2015 for the achievement of milestone 3 of the contract.

The Company also subsequently received a payment of €439,819 (approximately US $492,000) as part of a research and development grant for 2G BIOPIC, a project funded by the European Commission Horizon 2020 to develop advanced biofuels.  The project is being coordinated by Compagnie Industrielle de la Matière Végétale ("CIMV", a non-related entity). The agreement provides that the company will be paid a total of approximately €1.0 million over the three year term of the project. The purpose of the 2G BIOPIC project is to demonstrate the performance, reliability and sustainability, of the production processes for bioethanol extracted from agricultural residues and wood.

Net loss for the three month period ended March 31, 2015 was $0.4 million, or ($0.1) per basic and diluted share, compared to a net loss of $1.6 million, or ($0.05) per basic and diluted share, for the same period a year ago.

Total revenue for the three month period ended March 31, 2015 increased 35% to approximately $4.0 million compared to $3.0 million for the same period a year ago. Net product related revenue for the three month period ended March 31, 2015 increased 41% to approximately $3.5 million compared to $2.5 million for the same period a year ago. The increase in revenue for the period was driven by growth in the animal nutrition, biogas and food markets. License fee revenue for the three month period ended March 31, 2015 increased to $0.2 million due to the Company achieving a second research milestone with BASF. Research and development revenue for the three month period ended March 31, 2015 decreased 32% to approximately $0.4 million compared to $0.5 million for the same period a year ago.  The decrease in revenue for the period was due to mix and timing of project activity in commercial and government programs.

Gross profit for the three month period ended March 31, 2015 increased 70% to approximately $1.6 million compared to $0.9 million for the same period a year ago.  The $0.7 million increase in gross profit is attributable to (i) product related revenue growth of approximately $0.3 million, (ii) cost improvements in manufacturing, fermentation and down-stream processing of $0.4 million and (iii) the BASF research milestone of $0.2 million, (iv) partially offset by lower research & development margins due to mix and timing of commercial and government programs of $0.2 million.

General and administrative expenses for the three month period ended March 31, 2015 declined 44% to approximately $1.0 million compared to $1.7 million for the same period a year ago. The decrease primarily reflects lower litigation costs of approximately $0.6 million and lower professional service costs, stock based compensation and project related spending of $0.1 million.

Foreign currency exchange, net for the three month period ended March 31, 2015 was a loss of approximately $189,000, compared to a gain of $43,000 in the same period a year ago reflecting the strengthening US dollar versus the euro.

Chief Executive Officer, Mark Emalfarb, stated, “I am extremely pleased that our patented and proprietary C1 technology platform continues to achieve higher levels of enzyme purity, productivity, and performance. This has been validated by our ability to achieve two milestones sooner than anticipated with BASF resulting in the payment of $800,000 in April 2015. Additionally, Dyadic Netherlands now has four EU funded research programs scheduled to start in 2015, with aggregate funding approximating over €2 million to be received principally over the next three years.

“We are seeing a growing level of interest from the industry, as the global scientific and business community learns about the many benefits of working with our next generation ‘C1 White Strain 2.0’.  We   anticipate that this will lead to additional research and license revenue across expanded markets. Our enzyme business experienced strong revenue growth, improved gross profit and margins during the quarter. Additionally, we are making further progress in executing our business plan, which includes, among other things, plans to profitably grow our business and control costs.  As a result, we believe that the Company is on track to meet our objective of attaining profitability in 2016”.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com . Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote .

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic’s ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic’s research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic’s publicly available filings, including the risk factors included in Dyadic’s 2014 Annual Report filed with the OTC Markets Group on March 27, 2015.

The Company will host an investor conference call on Thursday, May 14, 2015 at 5:00 PM EDT, to discuss the Company’s first quarter financial results and provide a business outlook for the remainder of 2015.

In order to participate in the conference call, please dial 888-220-8449 within the U.S., or +913-312-0956 outside the U.S., using the call-in ID: 7726192.  The audio replay of the conference call will be on http://www.dyadic.com within 24 hours and available for a period of 15 days after the call.

Statements of Operations Information (Unaudited):  
   
DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES  
  CONSOLIDATED STATEMENTS OF OPERATIONS  
   
      Three Months Ended March 31,    
        2015           2014      
Revenue:    (Unaudited)     (Unaudited)   
Product Related Revenue, Net   $   3,478,317     $   2,459,160    
License Fee Revenue       200,000         -     
Research and Development Revenue       355,729         525,872    
                   
Total Revenue       4,034,046         2,985,032    
           
Cost of Goods Sold:       2,439,609         2,045,553    
                   
Gross Profit       1,594,437         939,479    
           
Expenses:          
General and Administrative       961,670         1,711,670    
Sales and Marketing        242,525         241,421    
Research and Development        405,153         450,633    
Gain on Sale of Fixed Assets       -          (11,600 )  
Foreign Currency Exchange Losses/(Gains), Net       188,513         (42,852 )  
                   
Total Expenses       1,797,861         2,349,272    
           
Loss from Operations       (203,424 )       (1,409,793 )  
           
Other Income (Expense)           
Interest Income       3,399         9,650    
Interest Expense       (180,631 )       (168,843 )  
Total Other Income (Expense)       (177,232 )       (159,193 )  
           
Net Loss   $   (380,656 )   $   (1,568,986 )  
           
Net Loss per Common Share          
Basic and Diluted   $   (0.01 )   $   (0.05 )  
           
Weighted Average Common Shares Used in Calculating Net Loss Per Share:          
Basic and Diluted       34,194,659         34,028,762    

 

Balance Sheet Information:  
   
        March 31, 2015     December 31, 2014 *  
        (Unaudited)        
                 
Cash and Cash Equivalents       $   3,657,522       $   2,495,455    
                 
Total Assets           10,637,994           8,535,353    
                 
Note Payable to Stockholder and Convertible Subordinated Debt           10,135,728           8,135,728    
                 
Accumulated Deficit           (84,881,070 )         (84,500,414 )  
                 
Stockholders' Deficit           (2,560,398 )         (2,264,762 )  
                 
* Condensed from audited financial statements.                

 

 

 

DYADIC CONTACT: Thomas Dubinski Chief Financial Officer Dyadic International, Inc. Tel: 561-743-8333 E-mail: tdubinski@dyadic.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 237

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
GALLS Honors Service With Lexington Hall of Fame Wall

Updated Category News Views 86

A headquarters wall can say more about a company than another polished mission statement ever will. On November 17, 2026, GALLS® unveiled the National Law Enforcement Officer Hall of Fame Wall at its Lexington, Kentucky, corporate headquarters, displaying portraits of every past inductee into the National Law Enforcement Officer Hall of Fame. Recognition, made permanent...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 58

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 115

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 32

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading

Top 5 Most Recently Viewed Articles

Coway's Inverter Dehumidifier 23L Triumphs at Global Design Awards

Updated Category News Views 208

Inverter Dehumidifier 23L Wins Recognition at Good Design Awards - The Inverter Dehumidifier 23L gains accolades for its compact design and user-friendly features at the Good Design Awards 2025. - This recent achievement cements Coway's status as a leading player in global design, recognized by all four major awards this year. Coway's Prestigious Award Recognition Hosted...

Continue Reading
Veru's Enobosarm & Semaglutide: A New Era in Weight Loss Safety

Updated Category News Views 314

Positive Safety Profile from Veru's Clinical Study Veru Inc. (NASDAQ: VERU), a trailblazer in biopharmaceuticals, recently revealed exciting topline safety results from its Phase 2b QUALITY clinical study. This trial examined the combination of enobosarm and semaglutide, uncovering significant advantages in safety and efficacy compared to semaglutide alone. Understanding...

Continue Reading
How a $1000 Investment in REV Group Can Grow Over Time

Updated Category News Views 180

Understanding REV Group's Market Performance REV Group (NYSE: REVG) has demonstrated impressive performance in the stock market over the past five years. This company has not only outperformed the broader market, but it has done so by a remarkable 29.45% on an annualized basis, resulting in an average annual return of 42.83%. With a market capitalization reaching...

Continue Reading
Castellum's GTMR Achieves Key CMMI Level 3 Milestone

Updated Category News Views 172

Castellum's GTMR Achieves Key CMMI Level 3 Milestone Castellum, Inc. (NYSE-American: CTM) has exciting news to share, as it announces its subsidiary, Global Technology and Management Resources, Inc. (GTMR), has achieved a significant milestone by obtaining a Level 3 appraisal under ISACA’s Capability Maturity Model Integration (CMMI). This recognition highlights GTMR's...

Continue Reading
Discovering Nature Close Up: The MicroCam X1 Launch

Updated Category News Views 162

Introducing the MicroCam X1 by Littpopo Littpopo, an innovative brand dedicated to exploration technology, has launched the MicroCam X1, a remarkable pocket microscope camera now live on a crowdfunding platform. This unique device combines a powerful 400X microscope with a 4K camera, making it an essential tool for educators, content creators, families, and adventurers...

Continue Reading